Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY (TAPESTRY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04481256
Recruitment Status : Recruiting
First Posted : July 22, 2020
Last Update Posted : January 20, 2021
Sponsor:
Collaborators:
UMC Utrecht
Catharina Ziekenhuis Eindhoven
Verbeeten Insituut Tilburg
Elisabeth-TweeSteden Ziekenhuis
Leiden University Medical Center
Radiotherapeutic Institute Friesland
Medisch Centrum Leeuwarden
Radiotherapy Group Deventer
Deventer Ziekenhuis
Rijnstate Hospital
Erasmus Medical Center
The Netherlands Cancer Institute
Maastro Clinic, The Netherlands
Zuyderland Medisch Centrum
Isala
University Medical Center Groningen
ZGT
Information provided by (Responsible Party):
H.W.M. van Laarhoven, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Brief Summary:
The primary objective of this study is to assess the feasibility of treatment with bintrafusp alfa combined with definitive chemoradiation (carboplatin, paclitaxel and radiation) in patients with squamous cell carcinoma of the esophagus or gastroesophageal junction.

Condition or disease Intervention/treatment Phase
Carcinoma, Squamous Cell Oesophageal Cancer Radiation: External beam radiotherapy Drug: Bintrafusp alfa Drug: Paclitaxel Drug: Carboplatin Not Applicable

Detailed Description:
Non-randomized feasibility study with paclitaxel, carboplatin, bintrafusp alfa, and radiation. Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36. Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg. External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 49 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Non-randomized feasibility study with paclitaxel, carboplatin, bintrafusp alfa, and radiation. Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36. Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg. External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
Actual Study Start Date : November 11, 2020
Estimated Primary Completion Date : June 1, 2023
Estimated Study Completion Date : June 1, 2023


Arm Intervention/treatment
Experimental: 1 Bintrafusp alfa, Paclitaxal, Carboplatin, Radiotherapy

Non-randomized feasibility study with paclitaxel, carboplatin, bintrafusp alfa, and radiation. Paclitaxel 50 mg/m2 and carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36. Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.

External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy

Radiation: External beam radiotherapy
External beam radiotherapy will be delivered to a total dose of 50.4 Gy in 28 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy

Drug: Bintrafusp alfa
Bintrafusp alfa will be given i.v. every three weeks on day 1, 22, and 43 at a dose of 2400 mg.

Drug: Paclitaxel
Paclitaxel 50 mg/m2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.

Drug: Carboplatin
Carboplatin AUC = 2 will be given intravenously (i.v.) on days 1, 8, 15, 22, 29 and 36.




Primary Outcome Measures :
  1. Feasibility difined as the percentage of patients completing at least two cycles of bintrafusp alfa [ Time Frame: 36 months ]
    The primary outcome of this study is the percentage of patients that completes at least two cycles of bintrafusp alfa together with their chemoradiotherapy regimen.


Secondary Outcome Measures :
  1. Incidence and severity of toxicity [ Time Frame: 36 months ]
    Incidence and severity of toxicity defined according to CTCAE v5 and and Radiation Oncology Group (RTOG) criteria.

  2. Percentage completion [ Time Frame: 36 months ]
    Percentage completion of chemotherapy and radiation treatment

  3. Percentage withdrawal rate [ Time Frame: 36 months ]
    Percentage withdrawal rate from chemoradiation due to bintrafusp alfa related complications

  4. locoregional progression [ Time Frame: 36 months ]
    Infield locoregional progression free survival

  5. progression [ Time Frame: 36 months ]
    Any progression free survival

  6. Survival [ Time Frame: 36 months ]
    Overall survival

  7. Quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ C30)) [ Time Frame: 36 months ]
    Overall Quality of life ranging from 0-100 with 100 being best Quality of Life with special focus on dysphagia

  8. adverse events [ Time Frame: 36 months ]
    To determine the number and grade of adverse events of bintrafusp alfa combined with chemoradiotherapy according to NCI common toxicity criteria (CTC) version 5


Other Outcome Measures:
  1. Biomarker [ Time Frame: 54 months ]
    To perform exploratory biomarker analyses for treatment response



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically proven squamous cell carcinoma of the esophagus or gastro esophageal junction.
  • Surgically irresectable (T1-T4a, N0 or N+, M0), as determined by Endoscopic Ultra Sound (EUS), PET scan and diagnostic CT scan of neck, thorax and abdomen. Patients with M1 disease solely on the basis of supraclavicular metastasis are eligible. Patients with resectable tumors refusing radical surgery are eligible.
  • Locoregional recurrences without distant metastasis after surgery alone or endoscopical resection
  • Locoregional recurrences without distant metastasis after neoadjuvant chemoradiation + resection or definitive chemoradiation outside the previously irradiated area, provided that full dose of radiation can safely be delivered.
  • Tumors that cannot be passed with an endoscope for endoscopic ultrasound are eligible if all other criteria are fulfilled.
  • If the tumor extends below the gastroesophageal (GE) junction into the proximal stomach, the bulk of the tumor must involve the esophagus or GE junction.
  • Age ≥ 18.
  • ECOG performance status 0-2 (cf. Appendix A).
  • Adequate hematological, renal and hepatic functions defined as:

    • Neutrophils ≥ 1.5 x 109/L
    • Platelets ≥ 100 x 109/L
    • Hemoglobin ≥ 5.6 mmol
    • Total bilirubin ≤ 1.5 x upper normal limit
    • ASAT and ALAT ≤ 1.5 x upper normal limit, Alkaline Phosphatase ≤ 2.5 x upper normal limit.
    • PT (INR) ≤ 1.5 x upper normal limit and aPTT ≤ 1.5 x upper normal limit.
    • Creatinine clearance (Cockroft) > 60 ml/min
  • Written, voluntary informed consent
  • Patients must be accessible to management and follow-up in the treatment center

Exclusion Criteria:

  • Past or current history of malignancy other than entry diagnosis interfering with prognosis of esophageal cancer.
  • Patient with tracheo-esophageal fistula or extension into the mucosal layer of the trachea, highly at risk to develop fistula. Thus, tumor extension to the trachea is allowed, but not through the trachea.
  • Patients with pathological lymph nodes at both supraclavicular and truncus coeliacus level.
  • Pregnancy (positive serum pregnancy test), planning to become pregnant, and lactation.
  • Patient (male or female) in the reproductive age is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment.
  • Previous chemotherapy, radiation and/or treatment with checkpoint inhibitors for the currently present esophageal tumor.
  • Previous chemotherapy and/or treatment with targeted agents and/or checkpoint inhibitors for other forms of cancer within the last six months.
  • Previous radiation to the mediastinum precluding full dose radiation of the currently present esophageal tumor.
  • Persisting grade >1 NCI CTCAE 5.0 toxicity (except alopecia and vitiligo) related to prior therapy; however, grade ≤2 sensory neuropathy is acceptable.
  • Presence of an esophageal stent.
  • History of bleeding diathesis or major bleeding event (grade ≥ 2) in the month prior to first dose of trial treatment.
  • Clinically significant cardiovascular disease precluding safe treatment with chemoradiation.
  • Evidence of pulmonary fibrosis and/or clinically significant impairment of lung function precluding safe treatment with chemoradiation. In case of doubt about pulmonary function, a lung function test should be performed and, in case of abnormalities, discussed with the principle investigator.
  • Serious underlying medical condition which would impair the ability of the patient to receive the planned treatment, including prior allergic reactions to drugs containing cremophor, such as teniposide or cyclosporine.
  • Mental status that would prohibit the understanding and giving of informed consent.
  • Inadequate caloric- and/or fluid intake despite consultation of a dietician and/or tube feeding.
  • Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine for patients with a history of autoimmune-related hypothyroidism, insulin for patients with type 1 diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Patients with vitiligo with dermatological manifestations only are eligible to enter the study.
  • A diagnosis of immunodeficiency or is receiving systemic steroid therapy (>10 mg/day prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
  • Diagnosis of HIV unless stable on antiretroviral therapy for at least 4 weeks, no evidence of multi-drug resistance, viral load of < 400 copies/ml and CD4+ T-cells ≥ 350 cells/µl.
  • Active HBV/HCV. Participants on a stable dose of antiviral therapy with HBV/HCV viral load below the limit of quantification are eligible.
  • Evidence of interstitial lung disease or active, non-infectious pneumonitis.
  • An active infection requiring systemic therapy, which has not resolved 3 days (simple infection such as cystitis) to 7 days (severe infection such as pyelonephritis) prior to the first dose of trial treatment.
  • Administration of a live vaccine within 30 days prior to the first dose of trial treatment. Seasonal flu vaccines that do not contain a live virus are permitted.
  • Patients with prior allogeneic stem cell or solid organ transplantation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04481256


Contacts
Layout table for location contacts
Contact: Linde Veen 020-5665955 l.veen1@amsterdamumc.nl
Contact: Hanneke WM van Laarhoven, MD, PhD 020-5665955 h.vanlaarhoven@amsterdamumc.nl

Locations
Layout table for location information
Netherlands
Academic Medical Center, Medical Oncology Recruiting
Amsterdam, Netherlands, 1100 DD
Contact: H WM van Laarhoven, MD, PhD, PhD    31 20 5665955    h.vanlaarhoven@amc.uva.nl   
Contact: Lyda ter Hofstede    31 20 5668229    trialmedonc@amc.uva.nl   
Principal Investigator: H. WM van Laarhoven, MD, PhD, PhD         
Sponsors and Collaborators
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
UMC Utrecht
Catharina Ziekenhuis Eindhoven
Verbeeten Insituut Tilburg
Elisabeth-TweeSteden Ziekenhuis
Leiden University Medical Center
Radiotherapeutic Institute Friesland
Medisch Centrum Leeuwarden
Radiotherapy Group Deventer
Deventer Ziekenhuis
Rijnstate Hospital
Erasmus Medical Center
The Netherlands Cancer Institute
Maastro Clinic, The Netherlands
Zuyderland Medisch Centrum
Isala
University Medical Center Groningen
ZGT
Investigators
Layout table for investigator information
Principal Investigator: Hanneke WM van Laarhoven, MD,PhD Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Layout table for additonal information
Responsible Party: H.W.M. van Laarhoven, Prof. dr., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ClinicalTrials.gov Identifier: NCT04481256    
Other Study ID Numbers: 73750
First Posted: July 22, 2020    Key Record Dates
Last Update Posted: January 20, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by H.W.M. van Laarhoven, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):
Definitive chemoradiation
TGF-beta inhibition
PDL-1 ihibition
feasability
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Squamous Cell
Esophageal Squamous Cell Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Esophageal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Paclitaxel
Carboplatin
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action